“Rising Focus on Targeted Therapy”
A significant trend driving growth in the pelvic cancer drug market is the increasing adoption of targeted therapy. Different from conventional treatments, targeted therapies focus on specific molecular targets associated with cancer, minimizing damage to healthy cells. This approach enhances treatment efficacy and reduces side effects, making it a preferred choice among patients and healthcare providers. For instance, drugs such as Bevacizumab (Avastin) are used for targeted treatment in pelvic cancers such as cervical cancer, blocking angiogenesis to inhibit tumor growth. With advancements in molecular biology and personalized medicine, the demand for targeted therapies continues to rise, bolstering market expansion and encouraging pharmaceutical innovation.
